Physician profile
David F Mercer
NPI 1104933878
$62,075.29
in general payments reported to CMS, 2019-2025
11 companies · $26K in 2025
The $26K reported for 2025 was more than what 96% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,032 · 2020: $3,916 · 2021: $10K · 2022: $759 · 2023: $11K · 2024: $2,089 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,292 · Travel and Lodging: $3,561 · Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,512.43 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,292.00 |
| Travel and Lodging | $3,561.30 |
| Food and Beverage | $1,738.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37,484.80 | 2020-2025 | Gattex |
| Zealand Pharma A/S | $15,702.38 | 2021-2023 | |
| Shire North American Group INC | $8,032.00 | 2019 | |
| Becton, Dickinson and Company | $229.73 | 2025 | Phasix Mesh |
| W. L. Gore & Associates, INC. | $133.72 | 2024 | Gore Seamguard Bioabsorbable Staple Line Reinforce |
| Abbvie INC. | $124.13 | 2024 | |
| Fresenius Kabi USA, LLC | $122.23 | 2023-2025 | |
| Alcresta Therapeutics, INC. | $120.16 | 2024 | Relizorb |
| Ironwood Pharmaceuticals, INC | $100.65 | 2024-2025 | |
| Davol INC. | $25.49 | 2023 | Phasix Mesh |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mercer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.